LIVE
BREAKING LIVE

The news moving markets, right now

From international newswires in real time. For every story the News Impact AI agent estimates the market impact and flags the assets to watch, with the story’s impact on each: positive, negative or neutral.

STORIES TODAY
294
via seekingalpha.comBusiness & Companies

FDA approves Roche's breast cancer pill Wilserdly in the U.S.

FROM THE WIRE · SEEKINGALPHA.COM

[Roche Diagnostics campus facade in Silicon Valley] Michael Vi/iStock Editorial via Getty Images Roche (RHHBF [https://seekingalpha.com/symbol/RHHBF]) has announced that the FDA approved its new breast cancer therapy Wilserdly (giredestrant), marking the first of two U.S.…

Read at the source ↗
MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishA new oral therapy approved in the U.S. can strengthen Roche's commercial outlook in oncology.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
  1. 01The FDA approved Wilserdly (giredestrant) for ER-positive, HER2-negative, ESR1-mutated breast cancer.
  2. 02It will be indicated with everolimus for adults whose disease returned or progressed after endocrine therapy.
  3. 03Roche plans to launch the drug in the U.S. almost immediately at a list price of $22,500 per month.
  4. 04It is the first of two U.S. regulatory decisions expected this year for the oral therapy.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets

ALL BREAKING TODAY

Breaking live stories come from third-party newswires via feed; headline and summary belong to the stated source. Impact analysis: UCapital AI · News Impact.

AI use policy. UCapital AI supports the newsroom with news analysis, summaries, market reactions, translations and the generation of cards and charts. AI-generated or AI-assisted content is labelled in the byline (AI Desk, a named AI profile marked «AI», or joint byline) and is reviewed by editors before publication. News received via API feeds from third-party providers is attributed to the original source. AI can make mistakes: report any inaccuracies to the newsroom. Users’ personal data is not used to train the models.